Method of treating or inhibiting the development of brain inflammation and sepsis
OwnerMasako Nozakiinventor
Life of this patent
Estimating the term…
Abstract
A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation.
Claims24
A method for treating or inhibiting the development of a disease, disorder or condition, which is associated with increased capillary permeability and white blood cell extravasations and selected from brain inflammation and sepsis, or symptoms thereof, comprising administering to a mammal in need thereof a therapeutically effective amount of a leukotriene C4 and D4 receptor antagonist or a pharmaceutically acceptable salt thereof, which does not cross or minimally crosses the blood brain barrier to treat or inhibit the development of the disease, disorder or condition, or symptoms thereof, with the proviso that when the method is treating or inhibiting brain inflammation, the brain inflammation is not caused by focal cerebral ischemia.
A method for treating or inhibiting the development of sepsis or the symptoms thereof, comprising administering to a mammal in need thereof a therapeutically effective amount of a leukotriene C4 or D4 receptor antagonist, or a pharmaceutically acceptable salt thereof.
A method for treating or inhibiting the development of brain inflammation, or the symptoms thereof, comprising administering to a mammal in need thereof a therapeutically effective amount of a leukotriene C4 and D4 receptor antagonist or a pharmaceutically acceptable salt thereof, which does not cross or minimally crosses the blood brain barrier to treat or inhibit the development of brain inflammation or symptoms thereof, wherein when the leukotriene C4 or D4 receptor antagonist is pranlukast or a pharmaceutically acceptable salt thereof, the therapeutically effective amount of pranlukast is in the range of about 400 mg/day to 800 mg/day.
A method for screening an inhibitor of increased capillary permeability, comprising:
- administering a potential candidate inhibitor compound to a non-human mammal before or after an inflammation-inducing agent is introduced into the subarachnoid space via a cannula inserted therein through the dura mater of the brain of the non-human mammal;
- measuring the amount of cerebrospinal fluid collected through the cannula;
- and
- determining from the measured amount of collected cerebrospinal fluid if the potential candidate inhibitor compound is an inhibitor of increased capillary permeability.
Dependencies are inferred from the claim text.